Compare PNFP & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNFP | MDGL |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | 3595 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3B | 12.1B |
| IPO Year | N/A | 2005 |
| Metric | PNFP | MDGL |
|---|---|---|
| Price | $98.49 | $520.47 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $111.20 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.2M | 355.7K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $160.52 | $58.39 |
| Revenue Next Year | $9.24 | $48.55 |
| P/E Ratio | $12.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $81.08 | $265.00 |
| 52 Week High | $120.39 | $615.00 |
| Indicator | PNFP | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 67.56 | 56.39 |
| Support Level | $92.97 | $503.93 |
| Resistance Level | $101.94 | $539.17 |
| Average True Range (ATR) | 2.44 | 16.69 |
| MACD | 0.89 | -1.95 |
| Stochastic Oscillator | 91.58 | 38.54 |
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.